Skip to content

Efficacy of Buteyko Breathing in Seniors With Chronic Eustachian Tube Dysfunction

Efficacy of Buteyko Breathing in Seniors With Chronic Eustachian Tube Dysfunction

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07193485
Enrollment
40
Registered
2025-09-25
Start date
2025-05-12
Completion date
2025-10-10
Last updated
2025-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eustachian Tube Dysfunction

Brief summary

Eustachian tube dysfunction is distressing probelm. drugs usually are not effective. compelemtary tehrapies like Buteyko breathing may be effective

Detailed description

forty seniors with Eustachian tube dysfunction (chronic obstructive form) will be ranomized to group I or group II. the group enroled 20 seniors. both groups wil take usual care (budesonide spray in nose in 64 microgram concentration one time per day plus the intake of a tablet two times daily containing containing 20-mg contration of pseudoephedrine hydrochloride and 5-mg concentration of loratadine) for 2 weeks. group I will aslo receive 30-min Buteyko breathing two times daily for 14 weeks.

Interventions

twenty seniors with Eustachian tube dysfunction (chronic obstructive form) will be ranomized to group I and this group will take usual care (budesonide spray in nose in 64 microgram concentration one time per day plus the intake of a tablet two times daily containing containing 20-mg contration of pseudoephedrine hydrochloride and 5-mg concentration of loratadine) for 2 weeks. Also, group I will aslo receive 30-min Buteyko breathing two times daily for 14 weeks.

OTHERusual care

twenty seniors with Eustachian tube dysfunction (chronic obstructive form) will be ranomized to group II and this group will take usual care (budesonide spray in nose in 64 microgram concentration one time per day plus the intake of a tablet two times daily containing containing 20-mg contration of pseudoephedrine hydrochloride and 5-mg concentration of loratadine) for 2 weeks.

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
65 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Eustachian Tube Dysfunction (chronic obstructive form) * unilateral ear affetion * senior patients * chronci affection more than 3 months

Exclusion criteria

* obesity * cardiac probelms repsiratory problems

Design outcomes

Primary

MeasureTime frameDescription
Eustachian Tube Dysfunction Questionnaireit will be measured after 2 weeksit will be used to asses symptoms of Eustachian Tube Dysfunction

Secondary

MeasureTime frameDescription
diastolic blood pressureit will be measured after 2 weeksit will be measured manually by manual sphygmomanometer
respiratory rateit will be measured after 2 weeksit will assess breath number per minute
pulse rateit will be measured after 2 weeksit will assess pulse number per minute from radial artery
patient health questionnaireit will be measured after 2 weeksit will assess depression in patients
systolic blood pressureit will be measured after 2 weeksit will be measured manually by manual sphygmomanometer
perceived stress scaleit will be measured after 2 weeksit will assess stress in patients
short form 36 questionnaireit will be measured after 2 weeksit will assess quality of life in patients
profile of mood satusit will be measured after 2 weeksit will assess mood in patients
percenatge of tympanometry (type C)it will be measured after 2 weeksit will assess percenatge of type c tympanometry
state trait anxiety inventoryit will be measured after 2 weeksit will assess trait anxiety in patients

Countries

Egypt

Contacts

Primary ContactAli MA Ismail, lecturer
ali.mohamed@pt.cu.edu.eg01005154209
Backup ContactAli mohamed, lecturer
allooka2012@gmail.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026